Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Codeine phosphate [gastro-intestinal use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 15mg/5mL linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 15mg/5mL diabetic linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 3mg/5mL pediatric linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 15mg/5mL s/f linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate [analgesic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 25mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
phosphate de codéine 60 mg/mL, ampoule de 1 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 4.56mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 5mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Acetaminophen + alcohol + codeine phosphate 120mg/7%vv/12mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Acetaminophen + codeine phosphate 120mg/12mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate + promethazine hydrochloride 10mg/6.25mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate + pseudoephedrine hydrochloride + triprolidine hydrochloride 10mg/30mg/1.25mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 30mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Brompheniramine maleate+codeine phosphate+phenylpropanolamine hydrochloride 2mg/5mL 10mg/5mL 12.5mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Aspirin 325 mg and carisoprodol 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing aspirin and carisoprodol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing aspirin and butalbital and caffeine and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Acetaminophen + alcohol + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing aspirin and carisoprodol and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate + promethazine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Brompheniramine maleate+codeine phosphate+phenylpropanolamine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate + pseudoephedrine hydrochloride + triprolidine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate+kaolin 10mg/3g/10mL mixture |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Co-codamol 8mg/500mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Ibuprofen+codeine phosphate 300mg/20mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Fioricet with codeine 325mg/50mg/40mg/30mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing codeine and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Codeine phosphate hemihydrate (substance) |
Is a |
False |
Codeine phosphate |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 15 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
4 |
Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate hemihydrate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Codeine phosphate |
Inferred relationship |
Some |
|
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
3 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 20 mg and ibuprofen 300 mg prolonged-release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 20 mg and ibuprofen 300 mg prolonged-release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |